Assessment of genetic risk for myocardial infarction

Thrombosis and Haemostasis

Volumn 96, Issue 2, 2006, Pages 220-227

  Yamada, Yoshiji ^a,b   Matsuo, Hitoshi ^c   Segawa, Tomonori ^c   Watanabe, Sachiro ^c   Kato, Kimihiko ^d   Hibino, Takeshi ^d   Yokoi, Kiyoshi ^d   Ichihara, Sahoko ^a   Metoki, Norifumi ^e   Yoshida, Hidemi ^f   Satoh, Kei ^f   Nozawa, Yoshinori ^b  

^a MIE UNIVERSITY   (Japan)

^b GIFU INTERNATIONAL INSTITUTE OF BIOTECHNOLOGY   (Japan)

^c GIFU PREFECTURAL GIFU HOSPITAL   (Japan)

^d GIFU PREFECTURAL TAJIMI HOSPITAL   (Japan)

^e Reimeikyo Rehabilitation Hospital   (Japan)

^f HIROSAKI UNIVERSITY   (Japan)

Author keywords

Atherosclerosis; Coronary heart disease; Genetics; Myocardial infarction; Polymorphism

Indexed keywords

5,10 METHYLENETETRAHYDROFOLATE REDUCTASE (FADH2); ALANINE; HOMEODOMAIN PROTEIN; INSULIN PROMOTER FACTOR 1; LIPOPROTEIN LIPASE; SERINE; UNCLASSIFIED DRUG; VALINE;

ADULT; AGE; AGED; AMINO ACID SUBSTITUTION; ARTICLE; BODY MASS; CONTROLLED STUDY; DIABETES MELLITUS; FEMALE; FLUORESCENCE ANALYSIS; GENE LOCUS; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; HEART INFARCTION; HIGH RISK POPULATION; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; JAPAN; MAJOR CLINICAL STUDY; MALE; MULTIVARIATE LOGISTIC REGRESSION ANALYSIS; PREVALENCE; PRIORITY JOURNAL; RELIABILITY; RISK ASSESSMENT; RISK FACTOR; SEX; SMOKING;

AGED; CASE-CONTROL STUDIES; FEMALE; FLUORESCENT DYES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; MALE; METHYLENETETRAHYDROFOLATE REDUCTASE (NADPH2); MICROSPHERES; MIDDLE AGED; MODELS, GENETIC; MULTIVARIATE ANALYSIS; MYOCARDIAL INFARCTION; POLYMORPHISM, GENETIC; REGRESSION ANALYSIS; RISK;

EID: 33747117971     PISSN: 03406245     EISSN: None     Source Type: Journal    
DOI: 10.1160/TH06-02-0117     Document Type: Article

References (47)

1. Burke W. Genomics as a probe for disease biology. N Engl J Med 2003; 349: 969-74.
2. Thom T, Haase N, Rosamond W, et al. Heart disease and stroke statistics - 2006 update: a report from the American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Circulation 2006; 113: e85-151.
3. Broeckel U, Hengstenberg C, Mayer B, et al. A comprehensive linkage analysis for myocardial infarction and its related risk factors. Nat Genet 2002; 30: 210-4.
4. Harrap SB, Zammit KS, Wong ZY, et al. Genomewide linkage analysis of the acute coronary syndrome suggests a locus on chromosome 2. Arterioscler Thromb Vasc Biol 2002; 22: 874-8.
5. Wang Q, Rao S, Shen GQ, et al. Premature myocardial infarction novel susceptibility locus on chromosome 1p34-36 identified by genomewide linkage analysis. Am J Hum Genet 2004; 74: 262-71.
6. Hauser ER, Crossman DC, Granger CB, et al. A genomewide scan for early-onset coronary artery disease in 438 families: the GENECARD Study. Am J Hum Genet 2004; 75: 436-47.
7. Cambien F, Poirier O, Lecerf L, et al. Deletion polymorphism in the gene for angiotensin-converting enzyme is a potent risk factor for myocardial infarction. Nature 1992; 359: 641-4.
8. Weiss EJ, Bray PF, Tayback M, et al. A polymorphism of a platelet glycoprotein receptor as an inherited risk factor for coronary thrombosis. N Engl J Med 1996; 334: 1090-4.
9. Iacoviello L, Di Castelnuovo A, De Knijff P, et al. Polymorphisms in the coagulation factor VII gene and the risk of myocardial infarction. N Engl J Med 1998; 338: 79-85.
10. Kuivenhoven JA, Jukema JW, Zwinderman AH, et al. The role of a common variant of the cholesterol ester transfer protein gene in the progression of coronary atherosclerosis. N Engl J Med 1998; 338: 86-93.
11. Topol EJ, McCarthy J, Gabriel S, et al. Single nucleotide polymorphisms in multiple novel thrombospondin genes may be associated with familial premature myocardial infarction. Circulation 2001; 104: 2641-4.
12. Yamada Y, Izawa H, Ichihara S, et al. Prediction of the risk of myocardial infarction from polymorphisms in candidate genes. N Engl J Med 2002; 347: 1916-23.
13. Ozaki K, Ohnishi Y, Iida A, et al. Functional SNPs in the lymphotoxin-a gene that are associated with susceptibility to myocardial infarction. Nat Genet 2002; 32: 650-4.
14. Ozaki K, Inoue K, Sato H, et al. Functional variation in LGALS2 confers risk of myocardial infarction and regulates lymphotoxin-α secretion in vitro. Nature 2004; 429: 72-5.
15. Shiffman D, Ellis SG, Rowland CM, et al. Identification of four gene variants associated with myocardial infarction. Am J Hum Genet 2005; 77: 596-605.
16. Itoh Y, Mizuki N, Shimada T, et al. High-throughput DNA typing of HLA-A, -B, -C, and -DRB1 loci by a PCR-SSOP-Luminex method in the Japanese population. Immunogenetics 2005; 57: 717-29.
17. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J Royal Stat Soc Ser B 1995; 57: 289-300.
18. Deloughery TG, Evans A, Sadeghi A, et al. Common mutation in methylenetetrahydrofolate reductase. Correlation with homocysteine metabolism and late-onset vascular disease. Circulation 1996; 94: 3074-8.
19. Ma J, Stampfer MJ, Hennekens CH, et al. Methylenetetrahydrofolate reductase polymorphism, plasma folate, homocysteine, and risk of myocardial infarction in US physicians. Circulation 1996; 94: 2410-6.
20. Schwartz SM, Siscovick DS, Malinow MR, et al. Myocardial infarction in young women in relation to plasma total homocysteine, folate, and a common variant in the methylenetetrahydrofolate reductase gene. Circulation 1997; 96: 412-7.
21. Kluijtmans LA, van den Heuvel LP, Boers GH, et al. Molecular genetic analysis in mild hyperhomocysteinemia: a common mutation in the methylenetetrahydrofolate reductase gene is a genetic risk factor for cardiovascular disease. Am J Hum Genet 1996; 58: 35-41.
22. Gallagher PM, Meleady R, Shields DC, et al. Homocysteine and risk of premature coronary heart disease. Evidence for a common gene mutation. Circulation 1996; 94: 2154-8.
23. Morita H, Taguchi J, Kurihara H, et al. Genetic polymorphism of 5, 10-methylenetetrahydrofolate reductase (MTHFR) as a risk factor for coronary artery disease. Circulation 1997; 95: 2032-6.
24. Mager A, Lalezari S, Shohat T, et al. Methylenetetrahydrofolate reductase genotypes and early-onset coronary artery disease. Circulation 1999; 100: 2406-10.
25. Schmitz C, Lindpaintner K, Verhoef P, et al. Genetic polymorphism of methylenetetrahydrofolate reductase and myocardial infarction: a case-control study. Circulation 1996; 94: 1812-4.
26. Folsom AR, Nieto FJ, McGovern PG, et al. Prospective study of coronary heart disease incidence in relation to fasting total homocysteine, related genetic polymorphisms, and B vitamins: the Atherosclerosis Risk in Communities (ARIC) Study. Circulation 1998; 98: 204-10.
27. Verhoef P, Rimm EB, Hunter DJ, et al. A common mutation in the methylenetetrahydrofolate reductase gene and risk of coronary heart disease: results among U.S. men. J Am Coll Cardiol 1998; 32: 353-9.
28. Klerk M, Verhoef P, Clarke R, et al. MTHFR 677C→T polymorphism and risk of coronary heart disease: a meta-analysis. J Am Med Assoc 2002; 288: 2023-31.
29. Lewis SJ, Ebrahim S, Smith GD. Meta-analysis of MTHFR 677C→T polymorphism and coronary heart disease: Does totality of evidence support causal role for homocysteine and preventive potential of folate? Br Med J 2005; 331: 1053-6.
30. Kastelein JJP, Jukema JW, Zwinderman AH, et al. Lipoprotein lipase activity is associated with severity of angina pectoris. Circulation 2000; 102: 1629-33.
31. Groenemeijer BE, Hallman MD, Reymer PWA, et al. Genetic variant showing a positive interaction with β-blocking agents with a beneficial influence on lipoprotein lipase activity, HDL cholesterol, and triglyceride levels in coronary artery disease patients. The Ser447-stop substitution in the lipoprotein lipase gene. Circulation 1997; 95: 2628-35.
32. Wittrup HH, Tybjærg-Hansen A, Nordestgaard BG. Lipoprotein lipase mutations, plasma lipids and lipoproteins, and risk of ischemic heart disease. A meta-analysis. Circulation 1999; 99: 2901-7.
33. Ukkola O, Garenc C, Pérusse L, et al. Genetic variation at the lipoprotein lipase locus and plasma lipoprotein and insulin levels in the Que'bec Family Study. Atherosclerosis 2001; 158: 199-206.
34. Kuivenhoven JA, Groenemeyer BE, Boer JMA, et al. Ser447stop mutation in lipoprotein lipase is associated with elevated HDL cholesterol levels in normolipidemic males. Arterioscler Thromb Vasc Biol 1997; 17: 595-9.
35. Jemaa R, Fumeron F, Poirier O, et al. Lipoprotein lipase gene polymorphisms: associations with myocardial infarction and lipoprotein levels, the ECTIM study. J Lipid Res 1995; 36: 2141-6.
36. van Bockxmeer FM, Liu Q, Mamotte C, et al. Lipoprotein lipase D9N, N291S and S447X polymorphisms: their influence on premature coronary heart disease and plasma lipids. Atherosclerosis 2001; 157: 123-9.
37. Chen W, Srinivasan SR, Elkasabany A, et al. Influence of lipoprotein lipase serine 447 stop polymorphism on tracking of triglycerides and HDL cholesterol from childhood to adulthood and familial risk of coronary artery disease: the Bogalusa heart study. Atherosclerosis 2001; 159: 367-73.
38. Yang Y, Ruiz-Narvaez E, Niu T, et al. Genetic variants of the lipoprotein lipase gene and myocardial infarction in the Central Valley of Costa Rica. J Lipid Res 2004; 45: 2106-9.
39. Humphries SE, Nicaud V, Margalef J, et al. Lipoprotein lipase gene variation is associated with a paternal history of premature coronary artery disease and fasting and postprandial plasma triglycerides: the European Atherosclerosis Research Study (EARS). Arterioscler Thromb Vase Biol 1998; 18: 526-34.
40. Henderson HE, Kastelein JJP, Zwinderman AH, et al. Lipoprotein lipase activity is decreased in a large cohort of patients with coronary artery disease and is associated with changes in lipids and lipoproteins. J Lipid Res 1999; 40: 735-43.
41. Zhang H, Henderson H, Gagne SE, et al. Common sequence variants of lipoprotein lipase: standardized studies of in vitro expression and catalytic function. Biochim Biophys Acta 1996; 1302: 159-66.
42. Ohlsson H, Karlsson K, Edlund T. IPF1, a homeodomain-containing transactivator of the insulin gene. EMBO J 1993; 12: 4251-9.
43. Inoue H, Riggs AC, Tanizawa Y, et al. Isolation, characterization, and chromosomal mapping of the human insulin promoter factor I (IPF-1) gene. Diabetes 1996; 45: 789-94.
44. Jonsson J, Carlsson L, Edlund T, et al. Insulin promoter-factor 1 is required for pancreas development in mice. Nature 1994; 371: 606-9.
45. Stoffers DA, Zinkin NT, Stanojevic V, et al. Pancreatic agenesis attributable to a single nucleotide deletion in the human IPF1 gene coding sequence. Nat Genet 1997; 15: 106-10.
46. Yamada K, Yuan X, Ishiyama S, et al. Identification of a single nucleotide insertion polymorphism in the upstream region of the insulin promoter factor-1 gene: an association study with diabetes mellitus. Diabetologia 1998; 41: 603-5.
47. Hansen L, Urioste S, Petersen HV et al. Missense mutations in the human insulin promoter factor-1 gene and their relation to maturity-onset diabetes of the young and late-onset type 2 diabetes mellitus in Caucasians. J Clin Endocrinol Metab 2000; 85: 1323-6.